Patents Represented by Attorney, Agent or Law Firm James R. Nelson
  • Patent number: 6172046
    Abstract: There is disclosed a method for treating a patient having chronic hepatitis C infection to eradicate detectable HCV-RNA involving a combination therapy using a therapeutically effective amount of ribavirin and a therapeutically effective amount of interferon-alpha for a time period of from 20 up to 80 weeks.
    Type: Grant
    Filed: September 21, 1997
    Date of Patent: January 9, 2001
    Assignee: Schering Corporation
    Inventor: Janice K. Albrecht
  • Patent number: 5552304
    Abstract: Plasmid vectors are provided that carry cDNA clones coding for polypeptides exhibiting B-cell, T-cell and mast cell stimulatory activities, all of which are enhanced in the presence of other immune-reactive agents. The polypeptides also augment the activity of various CSF's, such as G-CSF and G/M-CSF, and depress proliferation of macrophages in the presence of M-CSF. The cDNA is derived from mRNA isolated from a mammalian cell source, such as T-cells typically after activation with a mitogen. The plasmid vector also contains DNA segments from the SV40 virus, permitting expression of the cDNA after transfection into a mammalian host cell, such as COS cells. Two expressed polypeptides of the present invention from different mammals are about 140 and 150 amino acids in length, including potential leader sequences. An E. coli culture containing a plasmid (pcD-2A-E3) carrying a mouse cDNA insert of the present invention was deposited with the American Type Culture Collection (A.T.C.C.) on Nov.
    Type: Grant
    Filed: March 25, 1986
    Date of Patent: September 3, 1996
    Assignee: Schering Corporation
    Inventors: Frank Lee, Takashi Yokota, Ken-ichi Arai, Timothy Mosmann, Donna Rennick
  • Patent number: 5530125
    Abstract: A novel process for the preparation of .alpha.-substituted arylacetamides wherein the substituent is an aromatic group or a 1-alkenyl or 1-cycloalkenyl group and wherein the nitrogen atom carries no hydrogen atoms comprises the reaction of an arylacetamide having one or two hydrogen atoms on the .alpha.-carbon atom, wherein the nitrogen atom carries no hydrogen atoms, with a strong base in an inert aprotic organic solvent, followed by reaction with a zerovalent transition metal catalyst and then with a compound of the formula R.sup.4 --X, wherein R.sup.4 is selected from aromatic groups, 1-alkenyl groups and 1-cycloalkenyl groups and X is a particular leaving group, especially a triflate group. The .alpha.-substituted arylacetamides are useful as intermediates in the preparation (by reduction) of .alpha.-substituted arylethylamines, e.g., 1-substituted-2,3,4,5-tetrahydro-1H-3-benzazepines, having pharmacological activity. Certain benzazepines wherein the 1-substituent R.sup.4 is 1-(1-cycloalkenyl) are novel.
    Type: Grant
    Filed: August 19, 1994
    Date of Patent: June 25, 1996
    Assignee: Schering Corportion
    Inventors: Joel G. Berger, Wei K. Chang, Joseph A. Kozlowski, Guowei Zhou
  • Patent number: 5475087
    Abstract: Antagonists of GM-CSF are disclosed that comprise antibodies and anti-idiotypic antibodies specific for the carboxyl terminus of GM-CSF. These antagonists are useful for treating various diseases, the symptoms of which are increased by GM-CSF, and for lessening the effects of chemotherapy.
    Type: Grant
    Filed: February 4, 1994
    Date of Patent: December 12, 1995
    Assignee: Schering Corporation
    Inventors: Gail F. Seelig, Julie E. Scheffler, Paul P. Trotta
  • Patent number: 5463074
    Abstract: Disclosed is a compound of Formula I: ##STR1## or a pharmaceutically acceptable salt or solvate thereof. Also disclosed are pharmaceutical compositions comprising a pharmaceutically acceptable carrier and an effective amount of a Compound of Formula I.Further disclosed is a method of treating allergy (for example asthma), inflammation, hypertension, raised intraocular pressure (such as glaucoma)--i.e., a method of lowering intraocular pressure, sleeping disorders, states of hyper and hypo motility and acidic secretion of the gastrointestinal tract, hypo and hyperactivity of the central nervous system (for example, agitation and depression) and other CNS disorders (such as Alzheimers, Schizophrenia, and migraine) comprising administering an effective amount of a compound of Formula I to a patient in need of such treatment.
    Type: Grant
    Filed: June 15, 1994
    Date of Patent: October 31, 1995
    Assignee: Schering Corporation
    Inventors: Neng-Yang Shih, Robert Aslanian, Andrew Lupo, Jr., John J. Piwinski, Michael J. Green, Ashit K. Ganguly
  • Patent number: 5460956
    Abstract: A method for making crystals of interferon alpha-2 and the use thereof in depot formulations are disclosed.
    Type: Grant
    Filed: December 1, 1992
    Date of Patent: October 24, 1995
    Assignee: Schering Corporation
    Inventors: Paul Reichert, Gerald S. Hammond, Hung V. Le, Tattanahalli L. Nagabhushan, Paul P. Trotta
  • Patent number: 5451658
    Abstract: Novel synthetic polypeptides having amino acid sequences corresponding to the sequence of one or more specific regions of human gamma interferon are provided by this invention. These polypeptides specifically inhibit the binding of human gamma interferon to cellular receptors and the biological activity of such interferon. Antibody antagonists of the binding of human gamma interferon to cellular receptors based Upon the use of the polypeptides as antigens are also provided. Some of these antagonists bind to specific regions of gamma interferon which are believed to be involved in interactions between the intefferon and its receptors. Other antibody antagonists are anti-idiotypic antibodies which appear to compete directly with gamma interferon for binding to the cellular receptors. Also provided are methods for the use of the polypeptides and antibodies as inhibitors of the binding of gamma interferon to its cellular receptors.
    Type: Grant
    Filed: March 19, 1993
    Date of Patent: September 19, 1995
    Assignee: Schering Corporation
    Inventor: Gail F. Seelig
  • Patent number: 5446207
    Abstract: Compounds of the formula: ##STR1## wherein a is a single bond and b is a double bond; or a is a double bond and b is a single bond; and enantiomers thereof; or a pharmaceutically acceptable salt thereof are described. These compounds can improve lipoprotein profile of dyslipidemic patients and generate an anti-atherogenic lipoprotein profile of normolipidemic individuals. In addition, inhibition of CETP activity may be useful as antifertility agents.
    Type: Grant
    Filed: September 1, 1993
    Date of Patent: August 29, 1995
    Assignee: Harbor Branch Oceanographic Institution, Inc.
    Inventors: Shirley A. Pomponi, Vincent P. Gullo, Ann C. Horan, Mahesh G. Patel, Stephen J. Coval
  • Patent number: 5446069
    Abstract: Disclosed are compounds of formula ##STR1## wherein F represents: ##STR2## or a pharmaceutically acceptable salt. The compounds are useful in treating hyperproliferative skin disease, allergic reactions and inflamation.
    Type: Grant
    Filed: March 29, 1993
    Date of Patent: August 29, 1995
    Assignee: Schering Corporation
    Inventors: Neng-Yang Shih, Pietro Mangiaracina, Michael J. Green, Ashit K. Ganguly
  • Patent number: 5439916
    Abstract: Novel polycyclic quinoline, naphthyridine and pyrazinopyridine derivatives are disclosed which are useful for treating allergic reactions, inflammation, peptic ulcers, hypertension, and hyperproliferative skin diseases and for suppressing the immune response in mammals. Methods for preparing said compounds are also disclosed.
    Type: Grant
    Filed: August 31, 1990
    Date of Patent: August 8, 1995
    Assignee: Schering Corporation
    Inventors: Ashit K. Ganguly, Richard J. Friary, John H. Schwerdt, Marvin I. Siegel, Sidney R. Smith, Edmund J. Sybertz
  • Patent number: 5440033
    Abstract: Disclosed herein are compounds of the formula ##STR1## and pharmaceutically acceptable salts thereof, wherein Ar, R, X, and Y are as described herein are described. The compounds are useful for treating psychoses and depression and for providing analgesia. Compositions containing the compounds and methods for producing the compounds are also disclosed.
    Type: Grant
    Filed: November 9, 1993
    Date of Patent: August 8, 1995
    Assignee: Schering Corporation
    Inventors: Joel G. Berger, Joseph A. Kozlowski, Wei Chang
  • Patent number: 5438062
    Abstract: Derivatives of benzo[5,6]cyclohepta pyridine, and pharmaceutically acceptable salts and solvates thereof are disclosed, which possess anti-allergic and anti-inflammatory activity. Methods for preparing and using the compounds are also described.
    Type: Grant
    Filed: September 23, 1992
    Date of Patent: August 1, 1995
    Assignee: Schering Corporation
    Inventors: John J. Piwinski, Ashit K. Ganguly, Michael J. Green, Frank J. Villani, Jesse Wong
  • Patent number: 5437986
    Abstract: An insoluble mammalian protein is extracted from transformed bacteria expressing the mammalian protein while avoiding irreversible insolubilization of bacterial host proteins by homogenizing the fermentation broth, centrifuging the homogenized broth and removing the supernatant liquid for the inclusion body containing pellet. In another embodiment, the pH of the homogenized broth is adjusted to 2.0 prior to centrifugation. The acidified broth is then centrifuged, and the pellet is resuspended in buffer, homogenized again, and the inclusion body is isolated by centrifugation.
    Type: Grant
    Filed: June 22, 1994
    Date of Patent: August 1, 1995
    Assignee: Schering Corporation
    Inventors: Yair Alroy, Jingdong Zhu, Russell Condon
  • Patent number: 5432175
    Abstract: Pyridine and pyridine N-oxide derivatives of diaryl methyl piperidines or piperazines and pharmaceutically acceptable salts thereof are disclosed, which possess anti-allergic and anti-inflammatory activity. Pharmaceutical compositions containing and methods of using the compounds are also described.
    Type: Grant
    Filed: April 1, 1993
    Date of Patent: July 11, 1995
    Assignee: Schering Corporation
    Inventors: John J. Piwinski, Jesse Wong, Michael J. Green, Vera Seidl, Richard Friary
  • Patent number: 5422351
    Abstract: Bis-benzo or benzopyrido piperidene, piperidylidene and piperazine compounds of the formula: ##STR1## and pharmaceutically acceptable salts thereof are disclosed, wherein Z represents --(C(R.sup.a).sub.2).sub.m --Y--(C(R.sup.a).sub.2).sub.n -- or ##STR2## The compounds of Formula I possess anti-allergic and anti-inflammatory activity. Methods for preparing and using the compounds are also described.
    Type: Grant
    Filed: December 14, 1992
    Date of Patent: June 6, 1995
    Assignee: Schering Corporation
    Inventors: John J. Piwinski, Michael J. Green, Jesse Wong
  • Patent number: 5412104
    Abstract: Compounds useful as antihypertensive agents and useful as antiviral agents against DNA-containing viruses, such as herpes group viruses, are disclosed. The compounds are represented by Formula 1.0: ##STR1## and their pharmaceutically acceptable salts and solvates. Pharmaceutical compositions containing compounds represented by Formula 1.0 are disclosed. Methods of treating a viral infection using compounds represented by Formula 1.0 are disclosed.Also disclosed are methods of treating hypertension using compounds of Formula 1.0 wherein R is selected from the group consisting of H, halogen and --C(O)OR.sup.6 ; and R.sup.1 is selected from the group consisting of --OR.sup.14, --O(CH.sub.2).sub.a C(H).sub.3-i Z.sub.i and --O(CH.sub.2).sub.h N(R.sup.15).sub.2.
    Type: Grant
    Filed: March 1, 1993
    Date of Patent: May 2, 1995
    Assignee: Schering Corporation
    Inventors: Adriano Afonso, Jay Weinstein, Margaret J. Gentles
  • Patent number: 5362728
    Abstract: Novel benzazepines of the formula I: ##STR1## or a pharmaceutically acceptable salt thereof, wherein R represents H, alkyl, allyl or ##STR2## A represents --[CR.sup.1 R.sup.2].sub.n --; n represents 3 or 4; R.sup.1 and R.sup.2 may be the same or different and each independently represents H, OH, atkyl, alkoxy, phnenyl or substituted phenyl, with the proviso that R.sup.1 and R.sup.2 on the same carbon atom are not both OH, or R.sup.1 and R.sup.2 on the same carbon atom together represent=O;G represents H, R.sup.3 (CO)-- or ArNHCO--;R.sup.3 represents H, alkyl, alkoxy, phenyl or substituted phenyl;Ar represents phenyl or substituted phenyl; andY and Z may be the same or different and each is independently selected from H, halo, alkyl, alkoxy or halpalkyl;the pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, useful in the treatment of psychoses, drug dependence, D1 dependent neurological disorder or pain are disclosed.
    Type: Grant
    Filed: July 29, 1992
    Date of Patent: November 8, 1994
    Assignee: Schering Corporation
    Inventors: Theodros Asberom, Edward O'Connor, Joel G. Berger, John W. Clader
  • Patent number: 5352666
    Abstract: The present invention relates to ophthalmological pharmaceutical compositions comprising a renin inhibitor and to methods for using said composition in the treatment of glaucoma.
    Type: Grant
    Filed: December 14, 1989
    Date of Patent: October 4, 1994
    Assignee: Schering Corporation
    Inventor: Robert W. Watkins
  • Patent number: 5302716
    Abstract: Disclosed are fused benzazepine compounds, pharmaceutical compositions including such compounds, methods of using such compounds, for example, in the treatment of psychoses and/or depression, and intermediates useful in the preparation of such compounds.
    Type: Grant
    Filed: November 6, 1990
    Date of Patent: April 12, 1994
    Assignee: Schering Corporation
    Inventors: Joel G. Berger, Wei K. Chang, Elijah H. Gold, John W. Clader
  • Patent number: D384881
    Type: Grant
    Filed: May 31, 1995
    Date of Patent: October 14, 1997
    Assignee: Schering-Plough HealthCare Products, Inc.
    Inventors: Thomas Uhl, Ronald S. Elowitz, Robert C. Maxwell